Clinical Trials on Clindamycin Vs Metronidazole in Norway

Total 9 results

Oslo University Hospital

Completed

Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis (GVHD)

Graft-Versus-Host Disease

Norway
Oslo University Hospital

Completed

Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors (TG-CYANO)

Skin Closure of Surgical Incisions by Tissue Glue vs Suture

Norway
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Sirolimus in Kidney Transplant Recipients

Kidney Transplantation | Graft vs Host Disease

Norway, Sweden
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
St. Olavs Hospital
Oslo University Hospital; Norwegian University of Science and Technology

Completed

Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

Cutaneous T-Cell Lymphoma, Unspecified | Chronic Graft Versus Host Disease in Skin

Norway
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Korea, Republic of, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more

Clinical Trials on Clindamycin Vs Metronidazole in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations